Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Androgen receptor negatively regulated long non-coding RNA (ARNILA)
- Target
- ARNILA
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Androgen receptor negatively regulated long non-coding RNA (ARNILA) is a long non-coding RNA that is downregulated by androgen receptor activity and plays a significant role in promoting epithelial-mesenchymal transition, invasion, and metastasis in triple-negative breast cancer (TNBC)[1][2][4][5][6]. ARNILA functions as a competing endogenous RNA that binds miR-204, thereby facilitating SOX4 expression—a transcription factor driving EMT and cancer progression. High ARNILA expression correlates with poor progression-free survival in TNBC patients and may serve as a prognostic biomarker[1][2]. ARNILA is under investigation as a potential therapeutic target in aggressive breast cancer subtypes[1][3].
- Other names
- AR negatively induced lncRNAARSP-related lncRNAandrogen receptor negatively induced long non-coding RNA
02
Mechanism of action
Acts as a sponge for miR-204, enabling increased expression of SOX4, which induces EMT and metastasis in TNBC. Negative regulation by androgen receptor signaling.
03
Biological functions
Competing endogenous RNA (ceRNA) activityRegulation of epithelial-mesenchymal transition (EMT)Promotion of cell invasion and metastasis
04
Disease associations
CancerSpecifically: Breast cancer (notably triple-negative breast cancer, TNBC)
05
Safety considerations
No direct safety concerns reported. Therapeutic targeting would require consideration of effects on cellular RNA regulatory networks.
06
Biomarkers
Expression level of ARNILA as a prognostic biomarker for progression-free survival in triple-negative breast cancer patients
Beyond the preview
Go deeper on Androgen receptor negatively regulated long non-coding RNA (ARNILA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Androgen receptor negatively regulated long non-coding RNA (ARNILA).